RxDoctor Payments DataLook up a doctor →

Girendra Hoskere, MD

Pulmonary Disease · Bristol, TNNPI 1710970793

Payments from drug & device makers

$285,193in general payments, 2019–2025

Across 947 payments — averaging $301.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$249K
  • Regeneron Healthcare Solutions, Inc.$11K
  • Intuitive Surgical$11K
  • Amgen$5K
  • GSK$3K
  • Boehringer Ingelheim$1K
  • plus $5K from 32 others

What the payments were for

  • Consulting fees$9450%
  • Speaking & faculty fees$242,51285%
  • Travel & lodging$16,2576%
  • Food & beverage$19,6467%
  • Education$5,8192%
  • Gifts$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$285,193 in reported general payments places this provider in the 90th percentile of 339 pulmonary disease providers in Tennessee.

See all pulmonary disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$93,207
Medicare patients
460
Services billed
1,012

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$18,900
Breztri AerosphereBudesonide/Glycopyr/Formoterol23$17,136
Stiolto RespimatTiotropium Br/Olodaterol Hcl13$11,611
Albuterol Sulfate HfaAlbuterol Sulfate35$990
Prednisone23$124

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$2,555$18,90026 claims
AstraZenecaBreztri Aerosphere$248,744$17,13623 claims
Boehringer IngelheimStiolto Respimat$1,460$11,61113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 339 pulmonary disease providers in Tennessee.

Other pulmonary disease in Bristol

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →